Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Breast Cancer Female|HER2-positive Breast Cancer|Breast Cancer Stage II|Breast Cancer Stage III
Interventions: DRUG: Docetaxel|DRUG: Herceptin|DRUG: FEC|DRUG: Tamoxifen|DRUG: Letrozole|DRUG: LHRH agonist
Sponsor: University of Chicago